<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02796781</url>
  </required_header>
  <id_info>
    <org_study_id>201602102</org_study_id>
    <nct_id>NCT02796781</nct_id>
  </id_info>
  <brief_title>Autologous Lung Stem Cell Transplantation in Patients With Interstitial Lung Diseases</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai East Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Regend Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai East Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Interstitial lung diseases (ILD) are a group of diseases affecting the lung interstitium. The
      lung scarring that occurs in ILD is often irreversible with only mitigating therapy available
      so far. This study intends to carry out an open, single-armed, phase I/II clinical trial to
      investigate whether lung stem cells can regenerate damaged lung tissue. During the treatment,
      lung stem cells will be isolated from patients' own bronchi and expanded in vitro. After
      careful characterization, cultured cells will be injected directly into the lesion by
      fiberoptic bronchoscopy. The safety and efficacy of the treatment will be monitored by
      measuring the key clinical indicators.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Anticipated">April 2020</completion_date>
  <primary_completion_date type="Anticipated">April 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Increase of diffusing capacity of the lung for carbon monoxide (DLCO)</measure>
    <time_frame>3~48 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Increase of total lung capacity (TLC)</measure>
    <time_frame>3~48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Increase in 6 minute walk distance (6MWD)</measure>
    <time_frame>3~48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Life quality: assessed by St. George respiratory questionnaire (SGRQ)</measure>
    <time_frame>3~48 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Interstitial Lung Diseases</condition>
  <arm_group>
    <arm_group_label>lung stem cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive 10^6 (1 million)/Kg/person cells of clinical grade lung stem cells (LSCs)injected into lung via fiberoptic bronchoscopy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Lung stem cells</intervention_name>
    <arm_group_label>lung stem cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed with interstitial lung disease

          -  Clinically stable

          -  Written informed consent signed

        Exclusion Criteria:

          -  Allergic to cell therapy;

          -  Patients with serious significant pulmonary infection need anti-infection treatment;

          -  Patients who has taken amiodarone which may cause pulmonary fibrosis in the past 3
             months;

          -  Patients with malignant tumor in the past 5 years;

          -  Participated in other clinical trials in the past 3 months;

          -  Patients with serious heart disease(NYHA class Ⅲ-Ⅳ)

          -  Pregnant or lactating women;

          -  The investigator assessed as inappropriate to participate in this clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Tao Ren, M.D.</last_name>
    <email>rentao305@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wei Zuo, Ph.D.</last_name>
    <email>zuow@regend.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Regend Therapeutics</name>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <zip>215123</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wei Zuo, Ph.D.</last_name>
      <email>zuow@regend.cn</email>
    </contact>
    <contact_backup>
      <last_name>Ting Zhang, Ph.D.</last_name>
      <email>regendchina@hotmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Wei Zuo, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ting Zhang, Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yu Ma, Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shanghai East Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200123</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tao Ren, M.D.</last_name>
      <email>rentao305@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Lihua Bai, M.M.</last_name>
      <email>tongjiyixue@126.com</email>
    </contact_backup>
    <investigator>
      <last_name>Tao Ren, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Zuo W, Zhang T, Wu DZ, Guan SP, Liew AA, Yamamoto Y, Wang X, Lim SJ, Vincent M, Lessard M, Crum CP, Xian W, McKeon F. p63(+)Krt5(+) distal airway stem cells are essential for lung regeneration. Nature. 2015 Jan 29;517(7536):616-20. doi: 10.1038/nature13903. Epub 2014 Nov 12.</citation>
    <PMID>25383540</PMID>
  </reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 7, 2016</study_first_submitted>
  <study_first_submitted_qc>June 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 13, 2016</study_first_posted>
  <last_update_submitted>October 6, 2017</last_update_submitted>
  <last_update_submitted_qc>October 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai East Hospital</investigator_affiliation>
    <investigator_full_name>Wei Zuo</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Interstitial</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

